235 related articles for article (PubMed ID: 10566038)
21. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
[TBL] [Abstract][Full Text] [Related]
22. Drugs for inflammatory bowel disease.
Treat Guidel Med Lett; 2009 Sep; 7(85):65-74; quiz 75-6. PubMed ID: 19696709
[No Abstract] [Full Text] [Related]
23. The therapeutic spectrum of infliximab and tumor necrosis factor immunomodulation in chronic inflammatory diseases.
Ricart E; Bouma G; Peña AS
Drugs Today (Barc); 2002 Nov; 38(11):725-44. PubMed ID: 12582457
[TBL] [Abstract][Full Text] [Related]
24. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
Peyrin-Biroulet L
Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
[TBL] [Abstract][Full Text] [Related]
25. [TNF-alpha blocking therapy in chronic inflammatory bowel disease].
Molnár T
Orv Hetil; 2009 Sep; 150(38):1773-9. PubMed ID: 19740722
[TBL] [Abstract][Full Text] [Related]
26. [When can TNF-alpha inhibitors against inflammatory bowel disease be withdrawn?].
Moum B
Tidsskr Nor Laegeforen; 2007 Jun; 127(12):1673. PubMed ID: 17571118
[No Abstract] [Full Text] [Related]
27. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists.
Chowers Y; Sturm A; Sans M; Papadakis K; Gazouli M; Harbord M; Jahnel J; Mantzaris GJ; Meier J; Mottet C; Peyrin-Biroulet L; Allez M
J Crohns Colitis; 2010 Oct; 4(4):367-76. PubMed ID: 21122531
[TBL] [Abstract][Full Text] [Related]
28. TNF-alpha antagonists for the treatment of Crohn's disease.
Kam LY; Targan SR
Expert Opin Pharmacother; 2000 May; 1(4):615-22. PubMed ID: 11249506
[TBL] [Abstract][Full Text] [Related]
29. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects.
Allez M; Karmiris K; Louis E; Van Assche G; Ben-Horin S; Klein A; Van der Woude J; Baert F; Eliakim R; Katsanos K; Brynskov J; Steinwurz F; Danese S; Vermeire S; Teillaud JL; Lémann M; Chowers Y
J Crohns Colitis; 2010 Oct; 4(4):355-66. PubMed ID: 21122530
[TBL] [Abstract][Full Text] [Related]
30. Safety of infliximab in patients suffering from inflammatory bowel disease.
Felley C; Michetti P
Digestion; 2004; 70(1):1-2. PubMed ID: 15297772
[No Abstract] [Full Text] [Related]
31. [New molecules in the treatment of inflammatory bowel disease].
Chaparro M; Gisbert JP
Gastroenterol Hepatol; 2016; 39(6):411-23. PubMed ID: 26631943
[TBL] [Abstract][Full Text] [Related]
32. [Therapy of chronic inflammatory bowel diseases. TNF-alpha blocker in Crohn disease: earlier use is rewarding].
MMW Fortschr Med; 2008 Dec; 150(51-52):54-5. PubMed ID: 19156959
[No Abstract] [Full Text] [Related]
33. [Inflammatory bowel disease: anti-TNF strategies and beyond].
Hoffmann JC
Dtsch Med Wochenschr; 2004 Sep; 129 Suppl 2():S76-8. PubMed ID: 15368175
[No Abstract] [Full Text] [Related]
34. Induction of manic switch by the tumour necrosis factor-alpha antagonist infliximab.
Elisa B; Beny L
Psychiatry Clin Neurosci; 2010 Aug; 64(4):442-3. PubMed ID: 20653912
[No Abstract] [Full Text] [Related]
35. Peripheral neuropathy with infliximab therapy in inflammatory bowel disease.
Burger DC; Florin TH
Inflamm Bowel Dis; 2009 Dec; 15(12):1772. PubMed ID: 19170193
[No Abstract] [Full Text] [Related]
36. Increased hospitalizations in elderly with inflammatory bowel disease on anti-tumor necrosis factor therapy but not increased infections: a community practice experience.
Shen H; Lipka S; Katz S
J Crohns Colitis; 2014 Aug; 8(8):898-9. PubMed ID: 24434182
[No Abstract] [Full Text] [Related]
37. Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases.
Stevens BW; Borren NZ; Velonias G; Conway G; Cleland T; Andrews E; Khalili H; Garber JG; Xavier RJ; Yajnik V; Ananthakrishnan AN
Dig Dis Sci; 2017 Jan; 62(1):197-206. PubMed ID: 27796768
[TBL] [Abstract][Full Text] [Related]
38. Guidelines for the management of inflammatory bowel disease in adults.
Carter MJ; Lobo AJ; Travis SP;
Gut; 2004 Sep; 53 Suppl 5(Suppl 5):V1-16. PubMed ID: 15306569
[No Abstract] [Full Text] [Related]
39. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies.
Bendtzen K; Ainsworth M; Steenholdt C; Thomsen OØ; Brynskov J
Scand J Gastroenterol; 2009; 44(7):774-81. PubMed ID: 19140087
[TBL] [Abstract][Full Text] [Related]
40. Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease.
Cheon JH
J Gastroenterol Hepatol; 2017 Apr; 32(4):769-777. PubMed ID: 27723166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
